TAMPA, Fla.--(BUSINESS WIRE)--Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI) today announced that Med Ad News, a leading pharmaceutical business and marketing magazine, has published a cover story featuring SinuNase™, as an intranasal therapy for chronic sinusitis expected to garner FDA approval and break the annual billion-dollar sales barrier.
